Abbott wins FDA approval for CardioMEMS HF smartphone app updates

• Abbott (NYSE:ABT) secured FDA approval for updates to its CardioMEMS HF System that introduce patient access to heart-pressure data via a smartphone application.
• The advancement strengthens Abbott's remote cardiac care portfolio within its medical device segment ahead of upcoming quarterly reports.
• Abbott stated that the app and Dynamic Treatment Plan feature are planned for release later in 2026 to help patients and clinicians proactively manage worsening heart failure.

Abbott (NYSE:ABT) received regulatory clearance from the U.S. Food and Drug Administration for major software capabilities connected to its implanted heart-monitoring platform.

The update introduces the CardioGuide HF App, allowing patients to directly view pulmonary artery pressure readings that often spike weeks prior to physical symptom onset.

The system relies on a permanently implanted sensor to track blood flow pressure from the heart to the lungs with high clinical precision.

Following the announcement, Abbott Laboratories' share price was up at $97.50.

Alongside visibility features, the approval covers a Dynamic Treatment Plan tool that gives clinicians the ability to transmit personalized medication adjustments directly through the software interface.

Commercial availability for the CardioGuide HF App and its treatment plan feature is slated for rollout across the United States later in 2026.